Eli Lilly to buy Boston biotech Kelonia for $3.25 billion
pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene remedy maker Kelonia Therapeutics for not less than $3.25 billion, the businesses introduced Monday. The acquisition will grant Indianapolis-based Lilly entry to Kelonia’s blood most cancers therapy known as KLN-1010 that genetically modifies sufferers’ immune cells with out requiring them to be faraway from the…